📰 Imux News
Imux News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Imux. Real-time updates on events, politics, business and more.
April 28, 2024
StockNews.com cut shares of Immunic (NASDAQ:IMUX – Free Report) from a hold rating to a sell rating in a research note published on Saturday morning. Separately, Brookline Capital Management reaffirmed a buy rating and set a $10.00 target price on shares of Immunic in a research report on Friday, April 5th. View Our Latest Report […]
February 16, 2024
Immunic (NASDAQ:IMUX – Get Free Report) will be announcing its earnings results before the market opens on Thursday, February 22nd. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Immunic (NASDAQ:IMUX – Get Free Report) last released its earnings results on Tuesday, November 14th. The company reported ($0.51) EPS for […]
February 7, 2024
Immunic, Inc. (NASDAQ:IMUX – Free Report) – Analysts at Leerink Partnrs issued their FY2028 earnings per share estimates for shares of Immunic in a research report issued to clients and investors on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.66) per share for the year. The consensus estimate […]
January 5, 2024
By Colin Kellaher Shares of Immunic rose more than 10% in premarket trading Friday after the biotechnology company said it struck a deal to raise up to $240...
October 14, 2023
Immunic (NASDAQ:IMUX – Free Report) had its price target lifted by Wedbush from $5.00 to $7.00 in a research note published on Tuesday, MarketBeat Ratings reports. The firm currently has an outperform rating on the stock. Separately, StockNews.com initiated coverage on Immunic in a research note on Thursday, October 5th. They issued a sell rating […]
August 18, 2023
StockNews.com began coverage on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note issued to investors on Thursday. The firm issued a sell rating on the stock. Separately, Wedbush reaffirmed an outperform rating and set a $5.00 price target on shares of Immunic in a research report on Friday, August 4th. View Our […]
August 17, 2023
Innovis Asset Management LLC purchased a new stake in Immunic, Inc. (NASDAQ:IMUX – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 80,773 shares of the company’s stock, valued at approximately $120,000. Innovis Asset Management LLC owned 0.18% […]
August 9, 2023
Wedbush restated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com started coverage on Immunic in a research note on Thursday, May 18th. They issued a sell rating on the stock. […]
August 5, 2023
Wedbush reaffirmed their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a research note published on Friday morning, RTT News reports. They currently have a $5.00 price target on the stock. Separately, StockNews.com initiated coverage on Immunic in a research report on Thursday, May 18th. They set a sell rating on the […]
July 28, 2023
Wedbush reiterated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Thursday morning, Benzinga reports. Wedbush currently has a $5.00 price target on the stock. Separately, StockNews.com began coverage on Immunic in a research report on Thursday, May 18th. They issued a sell rating on the stock. One […]